Truist Securities Maintains Buy on Praxis Precision Medicine, Raises Price Target to $715
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Truist Securities analyst Danielle Brill maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $700 to $715.
Truist Securities analyst Danielle Brill maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $700 to $715.